Business
Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models
Findings from non-GLP DIO mouse studies show effects on insulin-resistance-related biomarkers, adipose endocrine signaling, and qualitative liver histology findings consistent with lower hepatic steatosisFORT LAUDERDALE, Fla., May 18, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT) today announced updated preclinical data from non-GLP diet-induced obesity (DIO) mouse studies evaluating ALN1003, the Company's investigational oral metabolic therapeutic candidate. Across selected
About this update from Alaunos Therapeutics, Inc.
[{"type":"image","alt":"Alaunos Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Alaunos Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":71,"url":"https://media.zenfs.com/en/globenewswire.com/fc44db75cac831d4f86f998f912e409c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CrWvUWpu0J3G9uwgJULKQw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk5/https://media.zenfs.com/en/globenewswire.com/fc44db75cac831d4f86f998f912e409c","width":300,"height":71},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/CrWvUWpu0J3G9uwgJULKQw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk5/https://media.zenfs.com/en/globenewswire.com/fc44db75cac831d4f86f998f912e409c","width":300,"height":71}},"lazy":false},{"type":"text","content":"Findings from non-GLP DIO mouse studies show effects on insulin-resistance-related biomarkers, adipose endocrine signaling, and qualitative liver histology findings consistent with lower hepatic steatosis","length":204,"tagName":"p"},{"type":"text","content":"FORT LAUDERDALE, Fla., May 18, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT) today announced updated preclinical data from non-GLP diet-induced obesity (DIO) mouse studies evaluating ALN1003, the Company's investigational oral metabolic therapeutic candidate. Across selected biomarker and liver histology assessments, ALN1003 showed effects on insulin-resistance-related measures, adipose endocrine markers, and qualitative liver pathology findings relevant to metabolic syndrome biology. These findings support continued preclinical development of ALN1003 in metabolic syndrome and related conditions, including obesity, metabolic dysfunction-associated steatotic liver disease (MASLD) and insulin resistance.","length":741,"tagName":"p"},{"type":"text","content":"Metabolic syndrome is increasingly understood not as a collection of independent risk factors, but as a multi-organ, adiposity-associated disease state characterized by insulin resistance, dysfunctional adipose tissue, chronic low-grade inflammation, and hepatic lipid accumulation. Emerging research suggests that the biological quality and endocrine function of adipose tissue, rather than fat mass alone, plays a central role in disease progression. Within this framework, the preclinical profile of ALN1003 is notable in that it appears to engage several of t...